Next-Generation Sequencing: On Our Radar

 Change is the only constant in the market for next-generation sequencing, and the market opportunity in NGS is evidenced by a number of acquisitions, financing rounds, product launches, and approvals, but six events stand out.  Kalorama continues to track the sequencing market, most recently in our report, Next-Generation Sequencing Markets (report: http://www.kaloramainformation.com/redirect.asp?progid=89330&productid=10290041).

 Kalorama notes the following recent events:

  

  • DNAe was awarded a $51.9 Million Contract   to develop semiconductor DNA sequencing platform for rapid diagnosis of antimicrobial resistant infections and influenza, from the Biomedical Advanced Research and Development Authority (BARDA).  BARDA is a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS).   Also, DNAe will present new data on G-BSI Blood-to-Result Test for Rapid Identification of Bloodstream Infections at The Association for Molecular Pathology (AMP) 2016.
  • Illumina's Grail to Raise $1 Billion in Series B.  Grail was spun out of the genetic sequencing giant Illumina to develop its blood-based cancer testing service and  leverages Illumina’s gene sequencing technology.      
  • Oxford Nanopore announced £100M / $126M fundraising.
  • Foundation BRCA CDx becomes the first NGS companion test to get FDA approval  as it receives FDA approval of FoundationFocus™ CDxBRCA as a Companion Diagnostic for Rubraca for the treatment of women with ovarian cancer.
  • Roche Diagnostics announced it has decided to focus solely on the Genia Technologies platform, and terminated the company’s collaboration with Pacific Biosciences.  

 DNA sequencing has successfully penetrated the research market.  Today, this market is large, and is expected to continue to grow, despite funding issues and other challenges.  In addition, technology advances in knowledge of the genome, and in DNA sequencing technology/platforms, will continue to fuel the growth of diagnostic applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories, and also in IVD companies that sell kits to clinical labs